Publications

Members of the Metabolic Continuum Roundtable™ contribute important research to the public domain through peer-reviewed articles in medical journals. Below is a selection of recent research co-authored by Roundtable contributors. For a comprehensive search of metabolic-related research by Roundtable contributors and others, visit pubmed.gov.

Filter

March 2025

MASLD as a non-communicable disease.

Sookoian S, Pirola CJ, Sanyal AJ. Nat Rev Gastroenterol Hepatol. 2025 Mar;22(3):148-149. doi: 10.1038/s41575-025-01039-x.

Publications

Filter

MASLD as a non-communicable disease.

EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis.

Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors’ Perspective.

Non-invasive evaluation of steatosis and fibrosis in the liver in adult patients living with cystic fibrosis.

The Lipidomic Profile Discriminates Between MASLD and MetALD.

A European Survey to Identify Challenges in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLD.

Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis.

Effect of Target-Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function.

Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease.

Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes.

Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease.

Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction-Associated Steatotic Liver Diseases: A Pathway to Precision Medicine.

Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitis.

Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH).

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021.

Swept up in the tsunami: Pediatric and adolescent steatotic (fatty) liver disease.

MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials.

Is digital pathology the new standard in MASH trials?

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).

The fibroblast hormone endotrophin is a biomarker of mortality in chronic diseases.

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.

Envisioning how to advance the MASH field.

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.

Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis – prevalence, clinical impact, economic implications and management strategies.

Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity.

LiverAI: New tool in the landscape for liver health.

New and emerging treatments for metabolic dysfunction-associated steatohepatitis.

A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.

A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States.

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease.

Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.

Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.

The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.

Changing from NAFLD to MASLD: The implications for health-related quality of life data.

Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept study.

The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD).

Integrating genetic and socioeconomic data to predict the progression of nonalcoholic fatty liver disease.

Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.

Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?

Increases and decreases in liver stiffness measurements are independently associated with the risk of liver-related events in NAFLD.

The new hepatic steatosis nomenclature. No more NAFLD!

Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction-associated steatohepatitis.

High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.

Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis.

Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome.

Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.

Health-related quality of life in non-alcoholic fatty liver disease: A cross-cultural study between Spain and the United Kingdom.

Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.

BCG Vaccination-Associated Lower HbA1c and Increased CD25 Expression on CD8+ T Cells in Patients with Type 1 Diabetes in Ghana.

Cost-effectiveness of diagnosis and treatment of early gestational diabetes mellitus: economic evaluation of the TOBOGM study, an international multicenter randomized controlled trial.

PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.

Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: A qualitative exploration of challenges and barriers.

The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease.

The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.

Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver Disease.

Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis.

Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction.

Metabolic dysfunction-associated steatohepatitis (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) require urgent attention by primary care physicians and endocrinologists.

Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.

Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.

Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.

Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH.

Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial.

Nutrition assessment and MASH severity in children using the Healthy Eating Index.

Impact of Type 2 Diabetes on the Outcomes of Solid Organ Transplantations in the U.S.: Data From a National Registry.

Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease.

The Impact and Burden of Dietary Sugars on the Liver.

A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis.

Diabetes mellitus, energy metabolism and COVID-19.

A nutrigenetic precision approach for the management of non-alcoholic fatty liver disease.

Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS).

Looking for the best algorithm in diabetes population for advanced fibrosis detection: The best is the enemy of the good.

Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease.

Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.